# A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

Study · id `cardio:ct-nct05035082` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05035082](<https://clinicaltrials.gov/study/NCT05035082>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05035082

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1018 participants.

## Technical summary

Registry record NCT05035082. Randomized; no masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2025-06-18 (actual). Results posted on 2026-08-10.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1018 participants (enrolled count; ClinicalTrials.gov record NCT05035082, source copy `cardio:ctgov-nct05035082-2026-08-10`, retrieved 2026-10-26)
- Started: 2021-09-01 (actual) (ClinicalTrials.gov record NCT05035082, source copy `cardio:ctgov-nct05035082-2026-08-10`, retrieved 2026-10-26)
- Primary completion: 2025-06-18 (actual) (ClinicalTrials.gov record NCT05035082, source copy `cardio:ctgov-nct05035082-2026-08-10`, retrieved 2026-10-26)
- Completion: 2025-06-18 (actual) (ClinicalTrials.gov record NCT05035082, source copy `cardio:ctgov-nct05035082-2026-08-10`, retrieved 2026-10-26)
- Results first posted: 2026-08-10 (ClinicalTrials.gov record NCT05035082, source copy `cardio:ctgov-nct05035082-2026-08-10`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05035082, source copy `cardio:ctgov-nct05035082-2026-08-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05035082-2026-08-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
- Acronym: REALYSE
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): oral glucose-lowering medications (commercially available)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 1e5031dd29cd7d5a0c37b70bc71f0c7edb8f0bf5bbaa6a07e2664871eb66f1a1
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
